AD_____

Award Number: DAMD17-02-1-0495

TITLE: Cell Cycle Dependent Regulation of Human Progesterone
Receptor in Breast Cancer

PRINCIPAL INVESTIGATOR: Lisa K. Mullany
                         Carol A. Lange, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota
                           Minneapolis, MN 55455-2070

REPORT DATE: October 2004

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                        Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

REPORT DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE October 2004	3. REPORT TYPE AND DATES COVERED Annual Summary (19 Apr 2002 – 18 Sep 2004)

4. TITLE AND SUBTITLE
Cell Cycle Dependent Regulation of Human Progesterone Receptor in Breast Cancer

5. FUNDING NUMBERS
DAMD17-02-1-0495

6. AUTHOR(S)
Lisa K. Mullany
Carol A. Lange, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Minnesota
Minneapolis, MN 55455-2070

E-Mail: piers016@umn.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

The progesterone receptor (PR) is phosphorylated *in vitro* by CDK2 at a number of sites, including serine 400. We sought to investigate the regulation of serine 400. Expression of cyclin E or elevated CDK2 activity downregulated unliganded PR and overexpression of an activated CDK2 mutant stimulated an increase in liganded and unliganded PR transcriptional activity. PR Ser400 was specifically required for the ligand-independent increase in PR transcriptional activity, but was not required for progestin-induced PR transcriptional activity. PR was unresponsive to activated CDK2 in breast cancer cells with elevated p27. RNAi knock-down of p27 restored activated CDK2-induced PR activation. In addition, an activated-CDK2 mutant induced increased nuclear localization of unliganded PR; PR with an alanine in place of Ser400 failed to undergo nuclear localization in response to activated CDK2 and exhibited delayed nuclear localization in the presence of progestins relative to wt PR. These studies demonstrate that CDK2 can regulate liganded and unliganded PR transcriptional activity. PR Ser400 plays a key role in ligand independent transcriptional activity and mediates nuclear localization in response to CDK2. These studies demonstrate a direct mechanism for regulation of ligand-independent PR transactivity in human breast cancer cells.

14. SUBJECT TERMS
Cell cycle, CDK2, progesterone receptor

15. NUMBER OF PAGES
69

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

Table of Contents

Introduction:
Steroid hormones are required for normal breast development and play a key role in breast cancer. The steroid hormone progesterone regulates cell growth in the normal mammary gland and uterus by cell cycle phase -specific actions. Breast cancers are often characterized by increased growth factor signaling pathways and numerous cell cycle alterations, including decreased levels of p27 and increased levels of cyclins D1, D2 and E. Progestins, via the activation of progesterone receptor (PR), activate cyclin dependent kinase 2 (CDK2) and raise levels of cyclins D and E. PR are phosphorylated by CDK2 *in vitro* and *in vivo* at multiple sites including serine 400 (Ser400). In addition, breast cancer cell growth is controlled, in part by, cross-talk between steroid hormone and growth factor signaling pathways. The purpose of these studies is to investigate the role that growth factors and cell cycle molecules play on the regulation of PR by phosphorylation of Ser400.

Body
Specific Aim 1: Determine effects of cyclin E and CDK2 overexpression on PR-B expression.
Task 1: Measure PR protein levels following transient co-expression of either wild-type or S400A mutant PR in HeLa cell line with HA-tagged cyclin E and myc-tagged CDK2 or empty vector control. PR levels were found to be altered in the presence of activated CDK2 (appendix, Fig. 3B.)

Task 2: Measure PR protein levels following transient expression of Ad-cyclin E and Ad-CDK2 or adenoviral-GFP control in the T47D-YB breast cancer cells line. Adenoviral Cyclin E overexpression induced the loss of PR independent of ligand (appendix, Fig. 2D).

Task 3: Measure PR protein levels following transient expression of Ad-CDK2 or Ad-GFP into MCF7 and T47D cell lines stably expressing either wt or S400A mutant PR.
Production of cell lines stably expressing S400A PR was not feasible. S400A PR is expressed normally when transiently expressed. However, when stably expressed, S400A PR is expressed as a truncated protein.

Specific Aim 2: Determine effects of cyclin E and CDK2 overexpression on PR-B transcriptional activity.

Task 1: Measure PR transcriptional activity following co-transfection of either wt or mutant PR and HA-cyclin E, Myc-CDK2 and PRE-luciferase reporter gene in HeLa cells. *PR transcriptional activity was enhanced by activated-CDK2 in the presence and absence of ligand (appendix, Fig. 3B). S400A was required for the ligand-independent response (appendix, Fig. 3B, 5C & 8A).*

Task 2: Measure PR transcriptional activity following co-transfection of Ad-cyclin E, Ad-CDK2 and Ad-PRE luciferase reporter gene in MCF7 cells stably expressing either wt or S400A mutant PR. *Not feasible as described in task 3.*

Task 3: Measure expression of endogenous genes known to be regulated by progestins in stable cell lines expressing either wt or S400A mutant PR. *This task was invalidated due to the S400A stable cells lines which express a truncated form of PR.*

Specific Aim 3: Determine effects of cyclin E and CDK2 overexpression on cell growth.
Task 1: Stably transfect MCF7 and T47D breast cancer cell lines with S400A mutant PR. *Found not feasible as reported in Specific Aim 1, task 3.*

Task 2: Measure effects on cell growth following addition of ad-cyclin E, ad-CDK2 in MCF7 cells stably expressing either wt or S400A mutant PR by flow cytometry and FACS analysis of propidium iodine-stained nuclei. *Found not feasible as reported in Specific Aim 1, task 3.*

Additional work:

- R5020 regulates CDK2 levels and activity in T47D-YB cells. CDK2 activity and levels were measured at various time points since R5020 is known to induce CDK2 activity (appendix, Fig.1C). These studies were done as supporting data to the observation that PR Ser400 was phosphorylated by R5020 and various mitogens by at least 15 minutes. It was discovered that R5020 stimulated an increase in both CDK2 activity and levels by 15 minutes and 1 hour respectively.

- P27 is a transcriptional repressor of PR. Activated –CDK2 was overexpressed in different cells lines (appendix, Figs. 4 & 5) and it was observed that activated-CDK2 was not able to increase the PR transcriptional activity in cells that had high levels of p27 by Western Blot (appendix, Fig. 4B & 6A). If the increase in transcriptional activity was due to elevated CDK2 activity, then addition of the CDK2 inhibitor p27 would be expected to inhibit the ligand-independent effect. P27 inhibited the activated-CDK2 induced increase both in the presence and absence of ligand (appendix, Fig. 5B). In addition, knock-down of p27 by p27 RNAi (provided by Robert Sheaff, U of MN), would be expected to and did lead to an increase in PR activity due to elevated CDK2 activity (appendix, Fig. 6B).

- PR Ser400 phosphorylation is blocked by CDK2 inhibitors in response to EGF in T47D-YB cells (appendix, Fig. 2B). Transcriptional activity is

enhanced by EGF in p27 low MDA-MB-435 cells in the presence and absence of ligand (appendix, Fig. 5C).

- CDK2 regulates nuclear localization of PR via Ser400 phosphorylation. Imaging studies were performed and it was determined that activated-CDK2 plays a role in regulating PR localization within the cell as shown and described in appendix, Fig. 9B. In addition, it was determined that Ser400 is required for efficient nuclear translocation (appendix, Fig. 9A).

Key Research Accomplishments:

- Determined that Ser400 is highly regulated by ligand and mitogens.

- Verified that Ser400 is phosphorylated by CDK2.

- Determined that there is an increase in PR activity when CDK2 is no longer regulated by p27-/- cells.

- Determined that CDK2 activity regulates PR transiently expressed in HeLa cells.

- Determined that R5020 increases CDK2 levels, in addition to CDK2 activity.

- Discovered that p27 plays a role in limiting the transcriptional activity of unliganded PR and limits the effect of activated-CDK2 on increasing PR transcriptional activity.

- Determined that S400A PR undergo delayed nuclear translocation.

- Determined that S400A PR plays a role in CDK2-induced nuclear localization of PR.

Reportable Outcomes:
- Data was presented in an oral session at the 2003 Endocrine Society's 85th Annual Meeting.

- 2003 Award Recipient (1st place) for Department of Medicine Research Day.

- 2003 Louise M. Nutter Student Research award.

- 2003 & 2004 Guest lecturer for Department of Medicine Medical Fellow Summer Research Workshop. "Signal Transduction: Lab Theory and Techniques.

- 2002 & 2003 Guest lecturer for Graduate level course. Lecture entitled: "Cell Cycle; Normal Control" Microbiology, Immunology and Cancer Biology program, University of Minnesota.

- Pierson-Mullany LK, Skildum A, Faivre E, Lange CA. 2003. Cross-talk between growth factor and progesterone receptor signaling pathways: Implications for breast cancer cell growth. Breast Disease, 18: 21-31.

- Pierson-Mullany LK and Lange CA. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin dependent protein kinase (CDK2). Mol. Cell Biology (In press).

- PhD completed Sept, 2004.

- Postdoctoral position received at Hennepin County Medical Center in Minneapolis, Minnesota beginning Oct, 2004.

Conclusions

The data from these studies indicate that CDK2 activity is able to regulate liganded and unliganded PR transcriptional activity and nuclear localization. The unliganded CDK2-induced activity and nuclear translocation requires PR Ser400 and p27 limits PR activity. Cell cycle regulation of PR transcriptional activity may play an important role in breast cancers with a deregulated cell cycle resulting from upregulated cyclins and/or reduced p27 levels. Our results have uncovered a mechanism for hormone independent/cell cycle dependent regulation of PR in breast cancer cells, which frequently display upregulated cyclin molecules ($\approx$ 40%) and/or loss of cyclin/CDK inhibitors ($\approx$ 30%). These data suggest that patients with steroid receptor positive breast cancer may benefit from endocrine therapies that target both the estrogen and progesterone receptors as well as cell cycle or growth regulating pathways.

Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-Independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2 (CDK2).

Lisa K. Pierson-Mullany[1] and Carol A. Lange[1,2]*

Running title: Regulation of PR Ser400 by CDK2.

University of Minnesota Cancer Center, Departments of Pharmacology,[1] and Medicine (Division of Hematology, Oncology, and Transplantation),[2] University of Minnesota, Minneapolis, MN 55455.

*Corresponding author. Mailing address: University of Minnesota Caner Center, MMC 806, 420 Delaware St. SE, Minneapolis, MN 55455. Phone: (612) 626-0621. Fax: (612) 626-4915. E-mail: Lange047@tc.umn.edu

Word counts:

Abstract- 200

Material and methods- 1151

Introduction, Results and Discussion- 7017

ABSTRACT

Human progesterone receptors (PR) are phosphorylated by CDK2 at multiple sites, including Ser400. Herein, we have addressed the significance of phosphorylation of this residue. PR phospho-Ser400 specific antibodies revealed regulated phosphorylation of Ser400 in response to progestins and mitogens, and this correlated with increased CDK2 levels and activity. Expression of cyclin E elevated CDK2 activity and downregulated PR independently of ligand. Similarly, overexpression of activated mutant CDK2 increased PR transcriptional activity in the absence and presence of progestin. Mutation of PR Ser400 to alanine (S400A) blocked CDK2-induced PR activity in the absence, but not in the presence of progestin. PR was unresponsive to activated CDK2 in breast cancer cells with elevated p27, and RNAi knock-down of p27 partially restored CDK2-induced ligand-independent PR activation. Similarly, in p27-/- mouse embryonic fibroblasts, elevated CDK2 activity increased wt, but not S400A PR transcriptional activity in the absence of progestin. CDK2 induced nuclear localization of unliganded wt, but not S400A PR; liganded S400A PR exhibited delayed nuclear accumulation. These studies demonstrate that CDK2 regulates PR in the absence of progestins via phosphorylation of Ser400, thus revealing a novel mechanism for upregulated PR transcriptional activity in human breast cancer cells expressing altered cell cycle regulatory molecules.

INTRODUCTION

The steroid hormones estrogen and progesterone regulate breast development (29, 89) and contribute to breast cancer progression (29, 54). Breast cancer cell lines are used to model the effects of steroid hormones on cell proliferation and survival. Steroidal control of cell cycle progression takes place at defined points in the G1 phase of the cell cycle (52). Progesterone has either a stimulatory (25, 47) or biphasic effects (11, 23, 53) on human T47D breast cancer cell growth, dependent in part upon cell culture conditions and the presence of estrogenic stimuli. Cell cycle analyses of biphasic cell growth patterns indicate that following a single dose of progesterone, cyclin D1 and cyclin E levels initially increase as cells undergo S-phase entry. Cyclin-dependent protein kinase 2 (CDK2) activity peaks at approximately 16 hrs. Coincident with increased CDK2 activity, PR protein levels begin to decline. The CDK inhibitors p21 and p27 are then induced after this early proliferative phase leading to G1 arrest and PR levels slowly recover as cells exit the mitotic cell cycle. Cells are further growth inhibited in the presence of additional progesterone treatments (23, 53), but progestin-primed cells can be induced to grow by administration of growth factors (23). These studies demonstrate a complex interplay between PR and cell cycle regulators.

Several studies have demonstrated that cyclin D1 and p27 play important roles in normal mammary gland development (14, 49, 81, 82). Cyclin D1-/- mice have a deficiency in pregnancy-associated mammary gland development (16, 80). In addition, overexpression of cyclins D1, E and decreased expression of

3

the cyclin-dependent kinase inhibitor p27 are associated with the high growth rates seen in human breast cancers. For example, approximately 45%-50% of breast cancers overexpress cyclin D1 (5, 21). Furthermore, progression from normal breast tissue through invasive ductal carcinoma (77), high grade ductal carcinoma relative to low grade (77), and late-stage lesions (34) are all associated with increased expression of cyclin E. In addition, decreased expression of p27 occurs in 30% of breast cancers and is correlated with poor prognosis in primary breast cancers (7, 63, 87). Mouse models of breast cancer support a role for alterations in cell cycle molecules in progression of mammary epithelial cells to preneoplastic stages (69). Deregulated cell cycle molecules are predicted to augment breast cancer progression in part as a result of increased CDK activity. The relevant CDK targets in breast cancers remain unknown.

The progesterone receptor is highly phosphorylated, primarily on serine residues, by multiple kinases in a similar manner to other steroid hormone receptor family members (41, 85, 93). While the role of phosphorylation of steroid receptors is not fully understood, phosphorylation may influence promoter specificity (65), cofactor interaction (19), ligand dependent (78) and ligand-independent (39) transcriptional activities, receptor turnover (43) and nuclear association (66). In addition, steroid hormone receptor phosphorylation may serve to integrate signals initiated by growth factors in tissues under steroidal control. A number of endogenously regulated phosphorylation sites on human PR have been well defined (41, 93). For example, serines at positions 294 and

345 in PR are predominantly phosphorylated following treatment of cells with progestin (96). Ser400 is both basally phosphorylated and regulated by ligand in cells; Ser400 is a basally phosphorylated site *in vivo* (96, 97) and phosphorylated by cyclin-dependent protein kinase 2 (CDK2) *in vitro* (95). Of the 14 identified phosphorylation sites, 8 are known to be phosphorylated by CDK2 *in vitro* (36, 95). The consequence of PR phosphorylation by CDK2 is unknown, but suggests a mechanism for cell-cycle dependent regulation of PR. We therefore investigated the role of direct regulation of PR by CDK2 in breast cancer cells by mitogenic stimuli, including progestins.

We seek to better understand how phosphorylation of PR in response to elevated CDK2 activity serves to link cell cycle progression to steroid hormone responsiveness. Our data indicate that phosphorylation of PR Ser400 is regulated by CDK2 in response to ligand and peptide growth factors. Transcriptional activity of PR is increased by activated CDK2 in both the presence and absence of progestin. Unliganded PR are well-activated by CDK2 only in the absence of high levels of p27 protein, and Ser400 is required for ligand-independent CDK2-induced PR nuclear localization and transcriptional activity. These data have important implications for breast cancers with upregulated CDK2 activity and/or functional loss of p27 (1, 7, 14, 63, 87).

MATERIALS AND METHODS

PR Antibodies. A polyclonal antibody that recognizes the phosphorylated form of human PR Ser400 was produced using the peptide sequence - EASAR(pS)PRSYLV- (phosphorylated at Ser400) as an antigen (commissioned from Biosource International, Hopkinton, MA). Total PR was measured with a monoclonal antibody (Ab-8, NeoMarkers, Fremont, CA.).

Cell Lines and Reagents. T47Dco breast epithelial cells constitutively expressing both endogenous PR-A and PR-B isoforms of PR have been described (27). T47D-YA and T47D-YB cells were created from PR negative T47D-Y cells by stably reintroducing either the PR-A or PR-B isoform as described (27, 76). T47D-Y, YA and YB cell stocks were maintained in MEM media, containing phenol red, supplemented with 5% FBS. For experiments, plated cells were placed in MEM starvation media (unsupplemented serum-free media containing phenol-red) overnight prior to R5020 treatment. Omission of phenol-red from culture media had no effect on R5020-induced changes in cell cycle regulation or growth of T47D variant cell lines (data not shown). PR-null T47D42W cells (50) were provided by V. Craig Jordan (Northwestern University, Chicago) and wt and P27-/- mouse embryo fibroblast (MEF) cells containing a targeted deletion of the p27 gene (12), were obtained from Robert Sheaff (University of Minnesota) and maintained in DMEM media containing 10% FBS. HeLa cervical carcinoma cells were maintained in MEM media supplemented with 5% FBS. The CDK inhibitor Roscovatine (used at 700 nM) was purchased

from Calbiochem (La Jolla, CA). The CDK2-selective inhibitor, CDK2 inhibitor II (used at 70 nM), was purchased from Calbiochem (La Jolla, CA.). The progestin agonist R5020 (Promegestone) was obtained from DuPont-New England Nuclear (Boston, MA.). Adenoma cyclin E viral expression vector (Ad-cyclin E) was a gift from James DeGregori (University of Colorado Health Science Center, Denver, CO). P27 and p27 RNAi plasmid expression vectors and active cyclin E/CDK2 were gifts from Robert Sheaff (University of Minnesota).

Immunoblotting. For detection of total PRs, phospho-Ser400 PR, p27 and cyclin E, cells grown in 100 mm dishes were washed twice with PBS. The cells were collected and lysed in RIPA buffer [10 mM sodium phosphate (ph 7.0), 150 mM NaCl, 2 mM EDTA, 1% (vol/vol) Nonidet P-40, 0.1% (wt/vol) Sodium dodecyl sulfate, 1% sodium deoxycholate, 20 μg/ml aprotinin, 50 mM sodium fluoride, 200 μM Na_3VO_4, 0.1% (vol/vol) β-mercaptoethanol, and 1 mM phenylmethylsulfonyl fluoride.] Lysates were clarified by centrifugation for 10 mins at 21,910 X g at 4°C. Soluble proteins were quantified by the Bradford method (Life Technologies, Inc.) and equal amounts of protein were resolved by SDS-PAGE (7.5% for PR and 10% for cyclin E and p27). The proteins were transferred to nitrocellulose and immunoblotted with specific antibodies as described (23). Western blots shown are representative of a minimum of three separate experiments.

CDK2 Activity Assay. To measure CDK2 activity, T47D-YB cells were plated at 800,000 cells in 100 mm cell culture dishes in media with 5% FBS. After 24 hrs, the cells were incubated in basal media for 24 hrs then treated with R5020 for various times indicated in the figure legends. The cells were washed twice in PBS and collected in RIPA buffer as above. 75 µg of lysate was incubated with 200 ηg anti-CDK2 antibody (M2-G, Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr at 4°C. The antibody/lysate mixture was then incubated with 10µl of Protein G-Agarose (Roche Diagnostics, Indianapolis, IN) in a final volume of 500-600µl for 1 hr at 4°C. The immune-complexes were washed three times with RIPA buffer, 3 times with kinase buffer (50 mM Tris-cl pH 7.5, 10 mM $MgCl_2$, 5 mM DTT, 0.1 mg/ml BSA) and incubated in a kinase reaction mixture containing 2µg histone H1 (Sigma) as a substrate and 5 µCi of $[\gamma\text{-}^{32}P]$ for 15 minutes at 37° C. The reaction was stopped by adding sample buffer, boiled for 2 mins and electrophoresed on a 12.5% SDS-PAGE gel. As a negative control, a non-specific antibody of similar isotype was incubated with the lysate and Protein G-Agarose beads before incubating the beads in the kinase reaction mixture. As a positive control, purified active cyclin E/CDK2 complex (provided by Robert Sheaff, University of Minnesota) was added to the kinase reaction mixture. Determination of the CDK2 activity in wt p27-/- MEF cells was performed using the same assay conditions above except the cells were cultured in 10% FBS. Phosphorylated purified histone H1 substrate proteins were visualized by autoradiography. Data shown are representative of typical results from three separate experiments.

Transcription assays. HeLa, MDA-MB-435, wt p27 +/+ MEF's or p27-/- MEF cells were plated at 250,000 cells per well in 6-well dishes. After 24 hrs, cells were transiently transfected with various combinations of either wt PR or S400A PR (0.01-1.0 μg each), CDK2 (1μg), and PRE-2x-TATA-luc reporter plasmid (1μg) along with Renilla plasmid (10ng) as a control for transfection efficiency. Cells were transfected with Effectene transfection reagent according to the manufacturer's instructions (Qiagen Inc., Valencia, CA.). After 24 hrs incubation, the transfection reaction was replaced with either unsupplemented serum-free phenol-red containing DMEM or MEM media for 8 hours prior to treatment. Cells were collected following treatment with 10 nM R5020 or ETOH vehicle control for 18 hrs. Luciferase and renilla activity were measured according to the manufacturer's protocol (Promega Corp., Madison, WI). The data are representative of typical results from a minimum of three separate experiments. The data are presented as means +/- standard deviations of three replicates for each data point.

Viral infection of T47D-YB cells. 400,000 T47D-YB cells were plated and grown overnight in 60 mm dishes. The cells were then incubated with 400 plaque forming units adenovirus encoding cyclin E (Ad-cyclin E), or control empty vector virus, for 48 hrs in growth media containing 5% FBS. The cells were then washed, incubated overnight in non-supplemented MEM and treated with R5020

or vehicle control for 1 hour. Cell lysate was collected with RIPA buffer and separated by SDS-PAGE gel electrophoresis and subjected to Western blotting.

IHC and Confocal Microscopy. The immunohistochemistry (IHC) and confocal microscopy protocols used for these studies have been previously described (66). In brief, cells were seeded onto coverslips in six-well multidishes. After the appropriate treatments, the cells were washed, fixed by incubation in 1 ml of 3.7% paraformaldehyde in PBS for 10 min at room temperature (RT), and permeabilized by incubation in 1 ml PBS containing 0.5% triton X-100 for 5 min at RT. Cells on coverslips were incubated with primary antibody against PR (NeoMarkers, AB8) diluted 1:100 in 100 ul PBS containing 1% BSA for 1 hr at RT. After 5 washes in PBS, coverslips were incubated in secondary antibody (fluorescein isothiocyanate-conjugated goat anti-mouse; Santa Cruz Biotechnology, Inc.) diluted 1:100 in 100 ul PBS containing 1% BSA for 1 hour at RT. Cells on coverslips were subjected to direct fluorescence imaging using a Zeiss Atto Arc HBO 110W Upright Microscope (Carl Zeiss, Inc.). Samples were excited at 488 nm and analyzed at an emission of 522. The data are representative of typical results from three separate experiments.

RESULTS

Regulation of PR Ser400 by progestins, growth factors, and CDK2.

PR Ser400 was previously identified as a site that is basally phosphorylated *in vivo* (97) and phosphorylated by CDK2 *in vitro* (95). To investigate the regulation of PR phosphorylation at Ser400, a phospho-specific antibody was produced. Affinity purified PR phospho-Ser400 antibodies were then used to blot cell lysates from T47Dco cells expressing two isoforms of PR (97kDa PR-A and 120 kDa PR-B) independently of exogenously added estrogen (27, 76). PR null T47D cells served as negative controls (Fig. 1A). PR isoforms underwent a characteristic mobility upshift in the presence of the synthetic progestin, R5020, indicative of multi-site phosphorylation following ligand-binding (79). A faint band of phospho-Ser400 PR was detected in the absence R5020, confirming basal phosphorylation of this residue (97). There was a dramatic increase in PR-A and PR-B Ser400 phosphorylation following R5020 addition, while no phosphorylated bands were visible in PR null T47D cells. To confirm the specificity of PR phospho-Ser400 antibodies, the peptide antigen used to generate the antibody was added to the blotting mixture. The phospho-Ser400 peptide specifically blocked PR phospho-Ser400 antibody binding to PR phosphorylated at Ser400 (far right lanes) but not binding of the total PR antibody to PR-A and PR-B. These data demonstrate that phospho-Ser400 PR antibodies specifically recognize the phosphorylated form of PR Ser400 and that Ser400 is phosphorylated in response to ligand.

To characterize the kinetics of PR Ser400 phosphorylation in breast cancer cells, time courses of R5020 treatment were performed in T47Dco or T47D-YA and T47D-YB cells (76) engineered to stably express only PR-A or PR-

B (Fig. 1B). Cells were treated with R5020 for 0-24 hrs and harvested at various time points. As expected, PR was down regulated in response to ligand binding (56). Ligand-induced down regulation of PR-A occurs over a time course similar to that of PR-B when both isoforms are concurrently expressed in T47Dco cells. However, the time course of ligand-induced down regulation of total PR-A in T47D-YA cells was prolonged relative to T47Dco, while downregulation of PR-B in T47D-YB cells is more rapid relative to T47Dco cells expressing both isoforms, suggesting that PR-A may partially stabilize PR-B in the heterodimer when co-expressed. Phosphorylation of PR Ser400 increased after 15 minutes of R5020 treatment and was sustained over the course of PR downregulation. Since Ser400 is a CDK2 site and CDK2 activity is known to be regulated by progestins (23), CDK2 activity was measured following R5020 treatment in T47D-YB cells (Fig 1C). R5020-stimulated CDK2 activity increased at 15 minutes and continued to rise for up to 24 hours, with the largest increases in CDK2 activity, occurring at 1, 3 and 24 hours, relative to basal activity in vehicle treated controls. The rise in CDK2 activity at early time points (15 min) following progestin treatment is consistent with the time course of PR Ser400 phosphorylation. Additionally, R5020 treatment induced an increase in CDK2 protein levels over time beginning at 1 hour (Fig. 1C), suggesting that increased CDK2 activity was in part due to stabilization of cyclin-CDK2 complexes in response to upregulation of G1-phase cyclins by progestins (23, 84).

To determine if stimulation of mitogenic signaling pathways by peptide growth factors can regulate the phosphorylation of PR-Ser400 independently of

progestins, T47D-YB cells were treated with either R5020 or various mitogens (Fig. 1D). Total PR levels remained constant up to one hour following mitogen treatment. Basal levels of PR Ser400 phosphorylation varied somewhat between cultures. However, several mitogens (EGF, HRG, PMA, IGF and FBS) induced PR Ser400 phosphorylation and mimicked the time course and intensity observed with R5020. The similar pattern of PR-Ser400 phosphorylation in response to these agents suggests a convergence of signaling pathways leading to the phosphorylation of PR Ser400 in response to progestins and mitogenic growth factors.

To test the CDK2-dependence of PR Ser400 phosphorylation in response to R5020, cells were treated with a CDK2-specific inhibitor prior to addition of R5020 (Fig. 2A). T47D-YB cells that express only the B isoform of PR were blotted for total and phospho-Ser400 PR, following long-term R5020 treatment, to induce of PR downregulation. Cells were pretreated with or without a CDK2-specific inhibitor that interferes with the ATP-binding site of CDK2 (13). The R5020-induced phosphorylation of PR Ser400 was blocked by the CDK2 inhibitor, suggesting that phosphorylation of this site is indeed regulated by CDK2 *in vivo*. In addition, the CDK2 inhibitor blocked ligand-induced PR-downregulation, indicating a role for CDK2 in this process. To test the CDK2-dependence of PR Ser400 phosphorylation in response to EGF treatment, cells were pretreated with or without a CDK inhibitor followed by EGF for 1 hr (Fig. 2B). EGF stimulated increased PR Ser400 phosphorylation relative to basal levels. However, similar to the results with R5020 (Fig. 2A), phosphorylation of

13

PR Ser400 was blocked by the CDK inhibitor. Interestingly, blockade of CDK2 activity in the presence of EGF reduced the level of phospho-Ser400 PR to below basal levels, suggesting that regulation of this site is highly dynamic. These data (Fig. 2A and 2B) indicate that phosphorylation of this site is regulated by CDK2 *in vivo*.

To confirm that CDK2 activation can contribute to PR downregulation in response to ligand, HeLa cells stably expressing PR-B were infected with a cyclin E-expressing adenovirus (Ad-cyclin E). Adenoviral expression of cyclin E, led to an increase in CDK2 activity relative to adenoviral expression of control plasmid (Fig. 2C). Following adenoviral transduction, cells were then treated with or without R5020 for I hour (Fig. 2D). Again, R5020 increased the phosphorylation of Ser400 in the absence of Ad-cyclin E as expected (Fig. 2D). However, PR-B levels were greatly diminished in the presence of cyclin E overexpression regardless of R5020 treatment, suggesting that elevated CDK2 activity, stimulated by cyclin E overexpression, may alter PR protein synthesis or folding, or bypass the requirement for ligand in PR downregulation. Actin controls demonstrated the specificity of Ad-cyclin E effects on PR-B. PR levels decline at the peak of CDK2 activity following progestin treatment of human breast cancer cells (23). To determine if CDK2 activity mediates the regulaton of basal levels of wt PR protein, T47D-YB cells were treated for 12 hrs with and without a CDK2 inhibitor in three separate experiments (Fig. 2E). PR levels were slightly elevated in cells treated with a CDK2 inhibitor, suggesting that the relative levels

of CDK2 activity can regulate basal levels of PR in the absence of receptor ligands.

Activation of PR Transcriptional Activity by CDK2; Role of PR Ser400.

To further study the functional significance of PR Ser400 phosphorylation by CDK2, a mutant form of PR-B was produced that has a serine to alanine point mutation at position 400 (S400A PR-B). A western blot for total PR (Fig. 3A top) demonstrated that wt and S400A mutant PR-B co-migrate and respond to the synthetic progestin, R5020, similarly (by gel up-shift) when transiently expressed in HeLa cells. Importantly, the PR phospho-Ser400 antibody did not recognize S400A mutant PR. We then performed a time course of R5020 treatment to determine if wt and S400A PR-B undergo similar rates of ligand-dependent downregulation (Fig. 3A bottom). HeLa cells were transiently transfected with wt or S400A PR-B and treated without or with R5020 for 1-9 hrs (Fig. 3A). Both wt and S400A PR were significantly downregulated following 9 hours of R5020 treatment, although some S400A PR-B remained at this time point.

To determine the influence of CDK2 on PR transcriptional activity and protein levels, HeLa cells were transiently co-transfected with a PRE-luc reporter, a renilla reporter construct as a transfection control, either wt PR-B or S400A mutant PR-B, and control parental vector or a vector encoding an active CDK2 double-mutant (CDK2-TY) in which Thr14 has been mutated to Ala and Tyr15 has been mutated to Phe (38, 57) (Fig 3B). Mutant CDK2-TY is resistant to inactivation by Wee-1 kinase regulated phosphorylation at Thr-14 and Tyr-15 (30,

43). The transcriptional activity of both wt PR and S400A PR-B increased to a similar extent (10-15 fold) in the presence of R5020 (compare lanes 1&2 and 5&6). Addition of CDK2-TY enhanced the activity of liganded wt and S400A PR receptors (compare lanes 2&4 and 6&8). These data suggest that CDK2 enhances PR transcriptional activity in response to R5020 and that PR Ser400 is not required for induction of transcriptional activity by liganded PR. Surprisingly however, CDK2-TY significantly increased the transcriptional activity of wt PR-B, but not S400A PR-B, in the complete absence of ligand (lanes 3 and 7), suggesting that CDK2-mediated phosphorylation of Ser400 is required for this ligand-independent effect. Remarkably, the magnitude of CDK2-TY induced activation of wt PR-B approaches that induced in response to R5020 alone (compare lanes 2 and 3). A Western blot of the cell lysates from each condition shows that both wt and S400A PR-B are downregulated in response to R5020 (lanes 1&2 and 5&6) as expected (Fig.3A). In addition, CDK2-TY appeared to downregulate wt PR-B in the absence of R5020 (compare lanes 1 and 3). This effect is similar to the downregulation of PR by cyclin E overexpression and CDK2 activation shown in figure 2C. CDK2-TY also diminished the levels of S400A PR-B in the absence of ligand (compare lanes 5 and 7). However, in sharp contrast to wt PR-B, S400A PR-B protein accumulated following R5020 treatment in the presence of CDK2-TY (lane 8). Taken together (Figs. 2-3), these data suggest that CDK2 can regulate PR protein levels in a complex manner. In the absence of ligand, CDK2 activation mediates loss of PR protein which is independent of Ser400 (lanes 3&7 relative to lanes 1&5). However, PR Ser400 is

absolutely required for CDK2-induced turnover of liganded PR (compare lanes 4 and 8). The mechanism to explain these effects is unknown, but may involve differential effects of CDK2 on PR synthesis/folding and turnover (see Discussion).

Ligand-independent regulation of human PR transcriptional activity is seldom reported (4, 39). To verify that the increase in ligand-independent transcriptional activity of wt PR was due to activated CDK2, PRE-luciferase activity was measured in HeLa cells expressing either wt or S400A mutant PR and increasing concentrations of CDK2-TY (Fig. 3C). A dose-dependent increase in PRE-luciferase activity occurred with increasing concentrations of mutant CDK2-TY, suggesting that stimulation of wt-PR activity in the absence of ligand was due to activated CDK2. In contrast, CDK2-TY failed to increase S400A PR-B transcriptional activity under the same conditions, confirming that PR Ser400 is required for this ligand-independent PR response. Cells lacking PR or cells containing PR and a reporter construct in which the PRE was mutated to an estrogen responsive element failed to respond to CDK2-TY (data not shown), demonstrating that the effect of CDK2-TY on PRE driven transcription is not due to a non-specific increase in overall or basal transcription. Furthermore, CDK2-TY induction of PR transcriptional activity was blocked by RU486 (not shown and see Fig. 8D). These data demonstrate that PR Ser400 mediates ligand-independent PR transcriptional activity in response to elevated CDK2 activity.

P27 Limits CDK2 Induced PR Transcriptional Activity.

To confirm that the effect of activated CDK2 on ligand-independent PR-B transcriptional activity occurs in breast cancer cells, the above experiments (Fig. 3C) were performed in PR null MDA-MB-435 (Fig. 4A) and PR null T47D-Y (Fig. 4B) cell lines. Cells were transfected with wt or S400A PR-B, a PRE-luciferase reporter construct, a constitutive Renilla reporter construct, and increasing concentrations CDK2-TY cDNA. Similar to the results in HeLa cells (Fig. 3C), there was a dose-dependent effect of CDK2-TY on wt PR but not S400A PR transcriptional activity in MDA-MB-435 cells (Fig. 4A). However, in contrast to these results, CDK2-TY caused only a slight increase in wt and S400A PR-B transcriptional activity in T47D-Y cells relative to vector controls, and increasing the dose of CDK2-TY was without effect (Fig. 4B).

Since the absolute levels of CDK2 activity are determined by the relative presence of CDK2 inhibitory molecules, and breast cancers frequently display loss of p27 (7, 63, 86), we postulated that these cell-type differences may reflect differences in p27 expression between breast cancer cell lines (Fig. 4) and HeLa cells (Fig. 3C). Therefore, we performed a Western blot of p27 expression levels in these cell lines (Fig 5A). Lysates of wt (p27+/+) and p27 -/- mouse embryonic fibroblast cells (MEFs) were included as positive and negative controls, respectively. P27-/- cells are immortalized MEFs derived from knock-out mice with a targeted deletion of the CDK2 inhibitor p27. T47D-Y PR null cells and T47D-YB cells express elevated levels of p27 relative to HeLa and MDA-MB-435 cells, suggesting that p27 may block the stimulation of PR activity by activated CDK2 in T47D breast cancer cell lines (Fig. 4B). We reasoned that if the

increase in PR transcriptional activity is due to elevated CDK2 activity, then addition of p27 should block ligand-independent PR activation. P27, a control p27 mutant (p27^{ck-}) that is unable to bind and inhibit CDK2 activity (91) or a parental control vector were therefore co-transfected into MDA-MB-435 cells along with either wt or S400A PR-B, CDK2-TY or its parental control vector, and PRE-luciferase and Renilla reporters. Cells were then treated without or with R5020 for 18 hrs (Fig 5B). As in HeLa cells (Fig. 3B), CDK2-TY increased PR-B transcriptional activity in both the absence and presence of R5020 in MDA-MB-435 cells. Wild-type P27, but not p27^{ck-}, slightly diminished PR-B activity in the absence of CDK2-TY, but blocked the CDK2-TY induced increase in PR activity observed in both the absence and presence of ligand, suggesting that the increase in PR transcriptional activity induced by CDK2-TY overexpression (Figs. 3-4) was due to elevated CDK2 activity.

Regulation of PR Ser400 phosphorylation and activity in response to mitogens was also investigated in p27 low MDA-MB-435 cells (Fig. 5C). MDA-MB-435 cells were transiently co-transfected with a PRE-luciferase reporter, a renilla reporter construct as a transfection control with either wt or S400A PR and treated with R5020 or EGF. In the absence of EGF or CDK-TY, the basal and R5020-induced transcriptional activities of both wt and S400A PR were similar. As in previous experiments (Fig.3B and Fig. 5B), CDK2-TY greatly enhanced wt PR transcriptional activity in both the presence and absence of R5020, and the unliganded activity mapped to PR Ser400. Similarly, EGF enhanced ligand-dependent (40-50%) and ligand-independent (3-4 fold) wt PR transcriptional

19

activity, while only the ligand-independent transcriptional activity mapped to Ser400. These data suggest that EGF, which induces phosphorylation of PR Ser400 (Fig. 1D), can also induce ligand-independent PR transcriptional activity, presumably via CDK2 activation in breast cancer cells expressing relatively low levels of p27 and that PR Ser400 is required for this effect.

To test the effects of elevated CDK2 activity on endogenously expressed PR in cells that also express elevated levels of p27 (Fig. 5A), we measured PR transcriptional activity in T47D-YB cells (Fig. 6A). T47D-YB cells were co-transfected with PRE-luc and Renilla reporter plasmids, and either control vector or increasing concentrations of CDK2-TY. Similar to the results with PR-null T47D-Y cells transiently expressing PR (Fig. 4B), there was only a slight increase in PR transcriptional activity in T47D-YB cells co-transfected with CDK2-TY, and no effect of increasing the dose of this kinase (Fig. 6A). If elevated p27 in the T47D-derived cell lines functions to limit the transcriptional activity of PR, then knock-down of p27 protein expression using p27 RNAi is predicted to increase PR transcriptional activity in response to CDK2-TY and R5020. To demonstrate that p27 and p27 RNAi targets p27 expression, T47D-YB cells were transfected with expression vectors containing p27 RNAi and cell lysates were blotted with p27-specific antibodies (Fig 6B; Insert). Knock-down of p27 resulted in a 50-60% reduction of p27 relative to controls, and is limited to some extent by the efficiency of transient transfection (i.e. every cell contains p27). We then overexpressed p27 RNAi or control RNAi by transient transfection of the appropriate pSHAG expression vectors in T47D-YB cells along with PRE-

luciferase and Renilla reporter plasmids and either CDK2-TY or its parental control vector (Fig. 6B). As in Fig. 6A, CDK2-TY alone had no effect on PR transcriptional activity in these cells. P27 RNAi enhanced PR transcriptional activity in both the absence and presence of R5020, and partially restored the ability of CDK2-TY to increase PR transcriptional activities. Unliganded PR underwent a 2-fold induction the presence of p27 RNAi, and this increased further when p27 was also knocked down (2-3 fold). These data suggest that p27 acts to repress PR transcriptional activity in the presence and absence of progestins, and that p27 levels may serve to limit PR action in breast cancer cells.

PR Ser400 mediates ligand-independent PR Action in p27-/- MEFs.

To confirm a repressive role for p27 on the Ser400 mediated regulation of ligand-independent PR transcriptional activity, we again utilized p27-/- and p27+/+ MEF cell line models. Endogenous CDK2 activity was measured in unstimulated p27+/+ and p27-/- cells using an *in vitro* kinase assay with histone H1 as a substrate. p27-/- MEF cells have greatly elevated CDK2 activity compared to wild-type p27+/+ cells (Fig. 7A). We then transiently expressed either wt or S400A PR-B in these cells (Fig. 7B). Similar levels of both wt and S400A PR-B were expressed in both cell lines (lower panel). However, wt PR was more highly phosphorylated on Ser400 in the p27 -/- cells compared to p27+/+ cells, suggesting that the phosphorylation status of PR Ser400 is

21

inversely related to the level of p27 CDK2 inhibitor and directly related to the level of CDK2 activity.

To examine the effect of elevated CDK2 activity on PR transcriptional activity in MEF cells, either wt or S400A PR-B were transiently co-transfected with both PRE-luciferase and Renilla reporter plasmids, and cells were treated without or with R5020 (Fig. 8A). Similar to the results with HeLa (Figs. 3B) and MDA-MD-435 (Fig. 4A, 5B & 5C) cells, there was significantly greater R5020-induced PR transcriptional activity in p27-/- MEF cells with elevated CDK2 activity (Fig. 8A) relative to wt p27+/+ cells expressing either wt or S400A PR. In addition, wt and S400A PR reached a similar maximum level of transcriptional activity in both cell types indicating that Ser400 is not required for PR transcriptional activity in response to progestins. However, the transcriptional activity of unliganded wt PR-B, but not S400A PR-B, was elevated 9-fold in p27-/- cells relative to wt p27+/+ cells, confirming that elevated CDK2 activity induces increased PR transcriptional activity independently of progestin-binding and that Ser400 is required for this effect.

To test the PR dependence of ligand-independent PR activity in p27-/- MEF cells, PR concentration curves were performed. P27-/- cells were transfected with increasing levels of either wt or S400A PR-B and PRE-driven luciferase activity was measured as above (Fig.8B). Ligand-independent PR transcriptional activity increased with increasing levels of wt PR, but not S400A PR, indicating that the transcriptional response is PR dependent and requires PR Ser400. PRE-luc activity was similarly measured in p27 +/+ MEF cells

transiently expressing either S400A mutant or wt PR-B (Fig. 8C). As shown for T47D cells with high levels of p27 (Figs. 4B and 6A), increasing levels of either wt or S400A PR-B failed to induce PRE-driven luciferase promoter activity in cells containing functional p27, suggesting that the ligand-independent response of PR is a result of p27 deletion and consequent elevated CDK2 activity (note difference in scales between Figs. 8B and 8C). The progesterone receptor antagonist, RU486, abolished ligand-independent PRE-luc activity in p27-/- cells expressing wt PR (Fig. 8D). Additionally, no transcriptional activity was detected in the absence of transfected wt PR, indicating that endogenous glucocorticoid receptor was not responsible for these effects (not shown). These results suggest that when CDK2 is not under the negative control of the CDK2 inhibitor p27, there is a subsequent increase in PR transcriptional activity both in the absence and presence of ligand. Furthermore, PR Ser400 is required for ligand-independent activation of PR in response to elevated CDK2 activity.

PR Ser400 Mediates CDK2 Induced PR Nuclear Translocation.

Unliganded PR are located in the cytoplasm and nucleus and have been shown to rapidly shuttle between these compartments (24). Following treatment with progestins, liganded PR are entirely nuclear within 30-60 mins. To visualize the subcellular location of S400A PR-B relative to wt PR-B, imaging experiments were performed in intact cells (Fig.9A). HeLa cells were transfected with either wt or S400A mutant PR-B and treated with or without R5020 for 1 and 3 hours. Cells were fixed, permeabilized and immunostained with an antibody specific for

23

total PR. Wt PR localized to the nucleus within 1 hour of R5020 treatment. In contrast, S400A PR-B remained cytoplasmic following 1 hour of exposure to R5020, but was predominantly found in the nucleus after at least 3 hours of R5020 treatment. To confirm the differential kinetics of wt and S400A PR nuclear accumulation, cells expressing either PR protein were counted (100 each) and scored for exclusive nuclear PR staining at both 1 and 3 hrs post-progestin addition (Fig. 9B). Prior to R5020 treatment, approximately 75% of the cells expressing wt PR contained both nuclear and cytoplasmic receptors, while wt PR was exclusively in the nucleus of 25% of the transfected cells. R5020 treatment caused nuclear translocation in almost 100% of cells containing wt PR by 1 hr. In contrast, few S400A PR transfected cells contained exclusively nuclear PR before R5020 treatment and following a 1 hour exposure to this ligand (Fig.9B). However, S400A PR-B was localized in the nucleus of almost 100% of transfected cells after 3 hours of R5020 treatment, indicating that S400A PR undergo delayed nuclear translocation in response to progestins.

CDK2 may induce ligand-independent PR transcriptional activity in part by increasing PR access to the nucleus, perhaps via phosphorylation of Ser400. We therefore performed additional imaging experiments in intact cells to visualize the subcellular location of wt and S400A PR in the absence and presence of activated CDK2 (Fig. 9C). HeLa cells were co-transfected with either wt or S400A PR and mutant CDK2-TY or its parental control vector. In the absence of progestin, CDK2-TY induced the nuclear localization of wt PR in nearly 100% of transfected cells (Fig. 9C-D). In contrast, S400A PR was resistant to CDK2-

induced nuclear localization relative to wt PR. Quantification of transfected cells revealed nuclear localization of S400A PR in a minority of cells (Fig. 9D), indicating that PR Ser400 mediates PR nuclear localization in response to activated CDK2. Imaging studies were also performed in PR and CDK2-TY co-transfected MDA-MB-435 cells with similar results (not shown).

Finally, to determine if p27 could also alter PR subcellular localization via regulation of CDK2 activity, imaging studies were repeated in HeLa cells by co-transfection of wt PR-B and either wt p27 or the CDK-2 binding mutant of p27 ($p27^{ck-}$) (Fig. 9E). Transiently transfected HeLa cells were treated with R5020 for 1 hr to induce nuclear localization of wt PR. Overexpression of wt p27, but not the CDK2-binding mutant ($p27^{ck-}$), resulted in cytoplasmic PR localization in at least 20% of co-transfected cells. Taken together, these data confirm that PR translocation to the nucleus is mediated by multiple mechanisms (66). The classical ligand-dependent mechanism (24) does not require PR Ser400 phosphorylation, but occurs more efficiently (i.e. in under 1 hr) when Ser400 is phosphorylated (Fig. 9A). An alternate mechanism of PR-nuclear localization occurs independently of ligand, is induced by activated CDK2, and requires PR Ser400 phosphorylation (Fig. 9C).

DISCUSSION

CDK2 regulates PR transcriptional activity.

Our results define a novel role for elevated CDK2 activity in the regulation of PR transcriptional activity and subcellular localization. Furthermore, CDK2 phosphorylation of PR Ser400 is required for increased PR nuclear localization and transcriptional activity in the absence of added progestins. Studies using PR phospho-Ser400 antibodies confirmed previous reports (95) that PR Ser400 is basally phosphorylated in resting cells and that progestin treatment also increases phosphorylation at this site (Fig. 1). Additionally, several mitogens predicted to activate CDK2, rapidly induce PR Ser400 phosphorylation in the absence of steroid hormones. Although PR Ser400 can be phosphorylated *in vitro* by purified cyclin A/CDK2 (95), the inhibition of Ser400 phosphorylation by CDK2-specific inhibitors (Fig. 2A) in intact cells suggests that CDK2 or CDK2-dependent down-stream kinases phosphorylate endogenous PR at this site.

Progestins are known to regulate cell cycle molecules (23) and induce CDK2 activity (23). Herein, we found that progestins induce increased CDK2 activity as early as 15 minutes. Interestingly, however, CDK2 protein levels were also increased in response to R5020 (Fig. 1c). R5020 rapidly up-regulates cyclin D1 and cyclin E protein levels (23) in a mitogen-activated protein kinase (MAPK) -dependent manner (42). Similarly, MEK inhibitors block CDK2 protein up-regulation in response to R5020 (E. Faivre and C.A. Lange, unpublished results), suggesting that progestin-mediated activation of MAPK and upregulation of G1-phase cyclins may stabilize cyclin-CDK complexes, and thus increase CDK2

26

protein levels and activity. Phosphorylation of PR by CDK2 occurs on at least eight sites (36, 95-97), and may provide a highly sensitive means of positive feedback or "feedforward" regulation by steroid hormones. Similar to progestins, a variety of mitogens including peptide growth factors also stimulate rapid phosphorylation of PR Ser400, suggesting that MAPK activation leading to a rise in CDK2 activity is an important input to PR regulation (Fig.1).

Activated CDK2 increased the transcriptional activity of both wt and S400A mutant PR in the presence of progestin indicating that CDK2 activity is able to positively regulate liganded PR and that this regulation does not require Ser400 (Fig. 3B). Recent data indicates that increased phosphorylation of PR in S phase corresponds with an increase in PR transcriptional activity and that overexpression of either cyclin A or CDK2 enhanced both PR and androgen receptor activity in transiently transfected COS cells (55). These authors found that CDK2 altered PR function by increasing the recruitment of the SRC-1 coactivator to liganded PR. In agreement with our studies (Figs. 3B & 8A) CDK2 regulation of liganded PR did not map to any known PR phosphorylation sites (55). These studies demonstrate that phosphorylation events can regulate PR action at multiple levels.

Notably, our studies show that CDK2 or EGF induced a significant increase in ligand-independent PR transcriptional activity that mapped to PR Ser400 (Figs. 3B, 4A, 5C, and 8). Thus, phosphorylation of PR Ser400 by CDK2 may provide a mechanism for setting the basal level of PR transcriptional activity in response to changes in CDK2 activity during normal cell cycle progression or

27

in breast cancer. To date, there are few examples of ligand-independent activation of human PRs. Bamberger et al. (4) demonstrated ligand-independent PR transcriptional activity using an activating protein-1 (AP-1) driven promoter in human endometrial adenocarcinoma cells. Interestingly, addition of progestin dampened PR-dependent AP-1 activity. Most recently, Labriola et. al (39) reported that heregulin activation of c-erbB2 receptors mediated a modest increase in ligand-independent PR transcriptional activity in T47D breast cancer cells (39). Similarly, in MDA-MB-435 cells, EGF stimulated a 3-4 fold induction of PR transcriptional activity in the absence of ligand (Fig. 5C). In contrast, many pathways leading to ligand-independent regulation of the estrogen receptor-alpha have been reported (51), and growth factors are now recognized as an important input to ER-alpha action.

PR Transcriptional Activity and Turnover are Inversely Related.

The inhibition of ligand-dependent PR downregulation by the CDK2 inhibitor suggests a role for CDK2 activity in this process (Fig. 2A). In support of this interpretation, cyclin E overexpression and hyper-activation of CDK2 stimulated PR downregulation in both the absence and presence of ligand (Fig. 2C), and these conditions resulted in increased PR transcriptional activity (Fig. 3B). In addition, inhibition of CDK2 activity elevated PR protein levels in the absence of ligand (Fig. 2D). These observations are consistent with recent studies suggesting that there is a positive relationship between the rate of transcription factor protein turnover and transcriptional activity (72, 73). Although

28

many sites on PR are known to be phosphorylated, Ser294 is the only other site that has been functionally well characterized (43, 66, 78). Increased PR transcriptional activity, following ligand-induced phosphorylation of Ser294, located within a "destruction box" motif, is coupled to rapid cytoplasmic degradation of PR by the ubiquitin proteosome pathway (43, 66). Similarly, the location of Ser400 adjacent to an additional "destruction box" motif in the N-terminus of PR and upstream of AF-1, may suggest a role for regulation of PR ubiquitination by phosphorylation of Ser400. Recent evidence suggests transcriptional activation domains can be regulated by ubiquitination, a required event for the transcriptional activation of multiple transcription factors, from yeast VP16 (71) to human ER-alpha (67). Additionally, in contrast to wt PR, S400A PR protein accumulates in the presence of progestin when CDK2 activity is high (Fig. 3; lane 8), perhaps due to CDK-2 induced nuclear sequestration (Fig. 9C). Alternatively, Ser400 may play a role in PR protein production or the stepwise ATP-dependent process of PR folding in the absence of progestins (64), and/or PR protein turnover in their presence. Interestingly, PR Ser400 is predicted to be exposed on the surface of native PR, and is located in an accessible "hotspot" region for cleavage by proteases (3). The ability of CDK2 to regulate PR protein synthesis or folding, ubiquitination, and targeting to the 26S-proteasome via phosphorylation of Ser400 is the subject of a separate study.

P27 is a Transcriptional Repressor of PR

P27 limits the activity of unliganded PR (Figs. 5-6), presumably due to its ability to inhibit CDK2 activity. However, CDK inhibitors appear to have novel functions independently of their kinase subunits (45). For example, although the significance is unknown, cytoplasmic p27 can bind to and sequester GRB-2 from SOS/Ras complexes in mouse fibroblast cells and in breast cancer cells (45). Our studies in HeLa cells, breast cancer cells, and p27-/- MEF cells provide strong evidence that CDK2 is a positive regulator of PR action in the absence of progestins, and that p27 may act as a transcriptional repressor of PR, possibly due in part to retention of PR in the cytoplasm, an effect that requires p27 binding to CDK2 (Fig. 9E). During these studies a recent report demonstrated that p27 acts as a transcriptional repressor of the glucocorticoid receptor (GR) by investigating the phosphorylation and activation of GR in p27-/- MEFs (92). However, whether increased GR transcriptional activity in p27-/- cells relative to wt MEF cells was dependent on altered CDK2 activity or direct binding of CDK subunits or p27 to GR was not determined. Cell cycle regulatory molecules have been reported to interact with and regulate other transcription factors. In addition, the transcription factor, B-Myb, has been demonstrated to be a direct target of cyclin A/CDK2 (68). The transcriptional activity of B-Myb is enhanced by cyclin A/CDK2 phosphorylation (2, 33, 40, 68, 70, 99) and Poly(ADP-ribose) polymerase (PARP) may function as a co-factor that promotes cyclin/CDK2-dependent phosphorylation of B-Myb (75). Cyclin A1 binds directly to B-Myb *in vitro* and enhances its activity by phosphorylation (48). In contrast, Cyclin D1 binding to B-Myb does not require enzymatic activity (26) and there appears to

be an inverse correlation between cyclin D1/B-Myb association and transcriptional activity (8). Cyclin E has been reported to activate transcription when bound to DNA via a heterologous DNA binding domain and in a cell cycle-dependent manner; this requires both CDK2-cyclin E association and CDK2 kinase activity (35). Cyclins and CDKs have also been shown to regulate the transcriptional activity of ER-alpha (90, 100). For example, overexpression of cyclin A increased ER-alpha transcriptional activity in both the presence and absence of estrogen in a variety of cell types and this effect required CDK2 kinase activity (90). However, cyclin A was not shown to associate with ER-alpha in these studies. In contrast, cyclin D1 increased ER-alpha transcriptional activity by direct association with ER-alpha and this effect appeared to be independent of CDK kinase activity (100). Similarly, cyclinA/CDK2 has been reported to bind to PR (55), and we have recently noted cyclinE/CDK2 binding to PR (L. Pierson-Mullany and C.A. Lange, unpublished results). Direct binding of cyclin, CDK, or CDK-inhibitory molecules to PR may explain the relative resistance of wt unliganded PR to CDK2-dependent activation in T47D cells (Figs. 4 and 6). We are currently examining the ability of cell cycle regulatory molecules to bind to and modulate PR action.

CDK2 Regulates Nuclear Localization of PR Via Ser400 Phosphorylation.

PR is located in both the cytoplasm and the nucleus in the absence of progestins and accumulates in the nucleus in their presence. Imaging studies of wt and mutant PR indicate that Ser400 is important for efficient (i.e. timely)

progestin-induced nuclear localization of PR and required for nuclear translocation induced by activated-CDK2 in the absence of steroid hormone ligand (Fig. 9). Since PRs are located in both the cytoplasmic and nuclear compartments of unstimulated cells, it is unknown where in the cell CDK2 is able to phosphorylate PR. Although the CDK2 partners cyclin A and cyclin E are nuclear proteins, recent cell imaging data demonstrate that like PRs (24), cyclin E and cyclin A/CDK2 complexes dynamically shuttle between the nucleus and cytoplasm, suggesting that CDK2 may phosphorylate both cytoplasmic and nuclear substrates (30). Indeed, CDK2 has both nuclear and cytoplasmic targets including E2F (37, 94), NF-kappaB (61) the NPAT regulator of S phase-specific histone transcription (44, 98), p300/CBP co-activators (17), PRC1, a regulator of cytokinesis (32), and proteins involved in centrosome duplication, nucleophosmin NPM/B23 (58, 88) mouse Mps1/TTK (18) and CP110 (9). According to our imaging data (Fig. 9), a possible consequence of CDK2-regulated phosphorylation of PR Ser400 is to regulate nuclear accumulation and/or shuttling between the cytoplasm and nuclear compartments. We reported a similar role for phosphorylation of PR Ser294 in response to progestins or EGF (66). Phosphorylation regulates nuclear translocation of a number of transcription factors including NF*k*B, *c-rel*, dorsal, and yeast SWI5 (as reviewed in Jans et al., (31)). Similarly, CDK sites regulate maximal levels of nuclear accumulation of SV40 large tumor antigen (31) and other cell cycle regulated molecules such as CDC6, a regulator of initiation of DNA replication (62). Similar to CDK2 regulation of unliganded PR nuclear localization, studies from this lab have

demonstrated that MAPKs induce PR nuclear localization in the absence of progestin via phosphorylation of Ser294, but are not required in the presence of ligand (66). Unlike CDK2-induced PR transcriptional activation of PRE-driven promoters in the absence of progestins (Figs. 3-5), MAPK activation alone was unable to induce transcriptional activation of unliganded PRs measured on PRE-driven promoters (43), but was required for PR-dependent expression of IRS-1 (65), suggesting that different kinase inputs to PR can mediate changes in promoter specificity independently of ligand-binding.

Role of Cell Cycle Regulation of PR in Breast Development and Cancer.

Surprisingly, studies in knock-out mice have shown that cyclin E and cyclin-dependent kinase 2 (CDK2) are not required for cell proliferation or mouse development (6, 20, 59, 60). However, cyclin E is required for cells to exit the Go quiescent state and thereby enter the cell cycle, and for the process of endoreduplication in which cells replicate their DNA without cell division such as trophoblasts in the placenta (20). In addition, cells from cyclin E1 and E2 knock out mice are resistant to oncogenesis (20). Thus, although cyclin E and CDK2 are not necessary for the process of mitosis in otherwise normal cells, there are correlations between aberrant over-expression of cyclin E and D-type cyclins and/or loss of p27 and tumorigensis, including poor patient prognosis and resistance to chemotherapy in breast cancer patients (5, 7, 21, 77).

Cells systematically progress through the cell cycle in part due to the orderly synthesis of cyclins. Cyclins in turn modulate the progression of the cell

cycle by binding to their catalytic CDK partners. For example, during the G_1 phase of the cell cycle, cyclin D forms a complex with either CDK4 or CDK6 followed by cyclin E complex formation with CDK2. Cyclins play a critical role in regulating cell proliferation by responding to extracellular signals. Deregulation of cyclins or CDK activity could lead to oncogenesis by making the cells less dependent on growth factors (28). Studies with PR knock out mice indicate that PR plays a key role in lobulo-alveolar development and progesterone's proliferative signal is required to induce a high incidence of mammary tumors (29). Similarly, cyclin D1 is expressed in normal mammary epithelium during lobulo-alveolar development (81) and mice lacking cyclin D1 resemble PR knock-out mice, in that lobulo-alveolar development is blocked (16, 80). In addition, the importance of the suppressive role of P27 is apparent in p27-/- mammary epithelial cells, where elevated CDK2 activity positively regulates both cell proliferation and survival (14). Another recent study implicates p27 as important for normal mammary development (49), while loss of p27 is a frequent occurrence in breast cancer (7, 63, 87). Interestingly, steroid hormones and peptide growth factors share common targets in mammary epithelial cells such as c-myc, c-fos, cyclin D1 and D2, CDK2, pRb and CDK inhibitors (15, 83). In fact, growth factor signaling pathways have been shown to profoundly regulate PR independently of (39) or in combination with progestins (39, 41, 43). Taken together, these data emphasize the intimate connection between cell cycle control and regulation of PR action during normal mammary gland development and in breast cancer.

In summary, these studies indicate that CDK2 activity is able to regulate liganded and unliganded PR transcriptional activity and PR nuclear localization. In the absence of progestins, CDK2-induced PR transcriptional activity and nuclear translocation requires PR Ser400 and p27 limits PR action. Cell cycle regulation of PR transcriptional activity may occur in breast cancers with a deregulated cell cycle resulting from upregulated cyclins and/or reduced levels of cyclin/CDK inhibitors and thereby contribute to breast cancer progression (10, 22). Our results have uncovered a mechanism for hormone independent and cell cycle dependent regulation of PR in breast cancer cells and suggest that patients with steroid receptor positive breast cancer may benefit from endocrine therapies that target both estrogen and progesterone receptors (46) as well as growth regulating kinase pathways (74).

Imaging Processing Lab Core Facility) for excellent confocal microscopy technical assistance. This work was supported by Department of Defense Breast Cancer Research Program #DAMD17-02-1-0495 (to L. Mullany) and NIH R01-DK053825 (to C. Lange).

FIGURE LEGENDS

Figure 1. Regulation of PR Ser400 phosphorylation. A.) Characterization of PR phospho-Ser400 specific antibodies. T47Dco cells expressing endogenous PR-A and PR-B isoforms or PR-null T47D cells were treated with R5020 (+) or ETOH (-) vehicle control for 1 hour. Equal amounts of cell lysate (100 ug) were electrophoresed on 7.5% SDS-PAGE gels, transferred to nitrocellulose and blotted with antibodies specific for either total PR protein or PR phospho-Ser400 **(P400)**. As a control for the specificity of PR phospho-Ser400 antibodies, blots were incubated with antibodies in the presence or absence of a blocking peptide representing the peptide used to make the phospho-specific antibodies. **B. Time course of PR Ser400 phosphorylation.** T47Dco, T47D-YA and T47D-YB cells were treated with either R5020 for 0-24 hrs and Western blots were performed as in A to detect either total PR or phospho-Ser400 PR. **C. CDK2 activity in R5020 treated T47D-YB cells.** T47D-YB cells were treated for 0-24 hrs with either R5020 (+) or ETOH (-) vehicle control and CDK2 immune-complexes were purified and subjected to *in vitro* kinase assays, using histone H1 (HH1) as a substrate. Phosphorylation of HH1 was detected by autoradiography, quantified by phospho-imaging and presented as a bar graph. Western blots were performed to detect total levels of CDK2 in each cell lysate. **D. Mitogen-induced PR Ser400 phosphorylation.** T47D-YB cells were treated with various mitogens (R5020; 10nM, epidermal growth factor; 30ng/ml, phorbol myristate acetate; 10nM, insulin-like growth factor; 30 ng/ml, and fetal bovine serum; 10%) or vehicle control for 5-60 mins and cell lysates were subjected to

SDS-PAGE and immunoblotting with antibodies specific for either total PR or phospho-Ser400 PR. Results are representative of 2-3 independent experiments.

Figure 2. CDK2 activity decreases PR protein levels. A. CDK2 inhibitors block ligand-dependent PR Ser 400 phosphorylation and PR down-regulation. T47D-YB cells were pre-incubated with either vehicle control or a CDK2-specific inhibitor (CDK2 inhibitor II) for one hour and then incubated with or without R5020 for an additional 11 hours. Cell lysates were blotted for either total PR or phospho-Ser400 PR (**P400**). **B. CDK2 inhibitors block mitogen-induced phosphorylation of PR Ser400.** T47D-YB cells were pretreated with vector control (DMSO) or the CDK inhibitor Roscovatine (700nM) for 30 minutes and then treated with R5020 or EGF for 1 hour. Cell lysates were blotted for total PR or phospho-Ser400 PR (**P400**). **C. Adenoviral expression of cyclin E stimulates CDK2 activity.** HeLa cells stably expressing PR-B were infected with a cyclin E expressing adenovirus (**Ad-E**) or a control adenovirus (**Ad-control**) for 48 hrs. CDK2 activity in IgG-control or CDK2-immune-complexes was measured as above (in fig. 1) using HH1 as a substrate. Purified active cyclin E/CDK2 complexes (1-3 ng) were added to the reaction mixture as a positive control for CDK2 activity. **D. Adenoviral cyclin E induced loss of PR protein.** Western blots for total PR, phospho-Ser400 PR, cyclin E and β-actin were performed on cell lysates from HeLa cells stably expressing PR-B and transduced with either control adenovirus (**Ad-control**) or adenovirus expressing cyclin E (**Ad-E**) in the presence and absence of R5020 for 1 hr. **E. Inhibition of CDK2 activity**

stabilizes PR protein. T47D-YB cells were treated with a CDK2-specific inhibitor (CDK2 inhibitor II) or vehicle control (DMSO) for 12 hours. Western blots for total PR and actin were performed on cell lysates. Data from 3 separate experiments are shown.

Figure 3. CDK2 increases PR transcriptional activity in the presence and absence of progestin. A. Expression of S400A PR-B and time course of ligand-dependent wt and S400A PR downregulation. HeLa cells were transiently transfected with either wt or S400A mutant PR-B (1ug each) and treated with R5020 (+) or ETOH (-) vehicle control for 1 hr (upper panel) or for 1-9 hrs (lower panels). Equal amounts of cell lysates (100ug) were probed for total PR, phospho-Ser400 PR, or β-actin by Western blotting. **B. CDK2-induced transcriptional activity of wt and S400A PR.** HeLa cells were transiently co-transfected with PRE-driven luciferase and constitutive-Renilla reporter plasmids, either wt or S400A PR-B (100ng each), and either mutant activated CDK2 (**CDK2-TY**) or its parental control vector. Following treatment of cell cultures with R5020 for 18 hrs, PRE-luciferase activity was measured and normalized to Renilla controls. Cell lysates were also immunoblotted for total PR levels at the same time point (**lanes 1-8**). **C. CDK2 dose-dependence of PR transcriptional activity.** HeLa cells were transiently co-transfected with wt or S400A PR-B (100ng each) and PRE-luciferase and Renilla reporter plasmids, along with increasing amounts of mutant CDK2-TY cDNA. PRE-luciferase activity was measured and normalized to Renilla controls. Control cultures (vector) received

1.0 ug of parental vector control (for CDK2-TY). Results are representative of 3 independent experiments. The data are presented as means +/- standard deviations of three replicates for each data point.

Figure 4. Activated-CDK2 induces ligand-independent PR transcriptional activity in PR-null MDA-MB-435 (A) but not T47D-Y (B) breast cancer cells. A. PR-B activity in MDA-MD-435 cells. MDA-MB-435 cells were transiently transfected with wt or S400A PR-B along with PRE-luciferase and Renilla reporter plasmids and increasing concentrations of mutant CDK2-TY or its empty parental vector as a control (vector). PRE-luciferase activity was measured and reported as arbitrary units of Luciferase/Renilla. **B. PR-B activity in T47D-Y cells.** T47D-Y PR null cells were transiently transfected with either wt or S400A PR along with PRE-luciferase and Renilla reporter plasmids and increasing concentrations of CDK2-TY or its empty parental vector as a control (vector). PRE-luciferase activity was measured and reported as arbitrary units of Luciferase/Renilla. The data are presented as means +/- standard deviations of three replicates for each data point. Results are representative of 2-3 independent experiments.

Figure 5. CDK2 induced PR transcriptional activity is inhibited by the CDK2 inhibitor, p27. A. p27 expression in cell line models. Cell lysates from T47D-Y, T47D-YB, MDA-MB-435, HeLa, and p27-/- and p27+/+ MEF cells were electrophoresed on 10% gels and blotted for p27; β-actin served as a loading

control. **B. Reversal of CDK2-induced PR activity by p27.** MDA-MB-435 cells were transiently co-transfected with wt PR (100ng), mutant CDK2-TY in the presence and absence of either p27 or mutant p27^{ck-}, and the appropriate vector controls along with the PRE-luciferase and Renilla reporter plasmids. PRE-Luciferase activity was measured following treatment with either ETOH vehicle control or R5020 for 18 hours. **C. PR transcriptional activity is enhanced by ligand and EGF in MDA-MB-435 breast cancer cells.** MDA-MB-435 cells were transiently transfected with a PRE-luciferase reporter, Renilla reporter with wt or S400A PR (100ng) with or without CDK2-TY. Following treatment with R5020 (10nM) or EGF (30ng/ml) for 18 hrs, PRE-luciferase activity was measured and normalized to Renilla controls. The data are presented as means +/- standard deviations of three replicates for each data point. Results are representative of 3 independent experiments.

Figure 6. Ligand and mitogen-induced PR transcriptional activity is enhanced in cells with low levels of p27. A. Absence of CDK2-induced PR activity in p27-rich T47D cells. T47D-YB cells were transiently transfected with a PRE-luciferase reporter along with increasing concentrations of CDK2-TY. PRE-luciferase activity was measured and normalized to Renilla controls. Vector control cultures (vector) received 1.0 ug of parental vector control (for CDK2-TY). **B. p27 RNAi restores CDK2-induced PR transcriptional activity in T47D-YB cells.** T47D-YB cells were transiently transfected with PRE-luciferase and Renilla reporter plasmids, CDK2-TY (+) or its parental control vector (-), and pSHAG

41

vectors expressing either control RNAi (-) or p27 RNAi (+). Following treatment with R5020 (10nM) for 18 hrs, PRE-luciferase activity was measured and normalized to Renilla controls. **Inset: p27 RNAi knock-down of p27.** P27 RNAi or control RNAi were co-transfected into T47D-YB cells and cell lysates were blotted for p27 and β-actin. The data are presented as means +/- standard deviations of three replicates for each data point. Results are representative of 2-3 independent experiments.

Figure 7. PR Ser400 is highly phosphorylated in p27-/- relative to wt p27+/+ MEF cells. A. Endogenous CDK2 activity in MEFs cells. Endogenous CDK2 in lysates from unstimulated wt p27+/+ and knock-out p27-/- MEFs was purified by immunoprecipitation using CDK2-specific antibodies and immune-complexes were assayed in *in vitro* kinase assays using HH1 as a substrate. Controls included non-specific IgG immunoprecipitates (IgG control) and purified recombinant active cyclinE/CDK2 as a positive control for CDK2 activity. **B. Increased PR Ser400 phosphorylation in p27-/- MEF cells.** wt PR or S400A PR were transiently transfected into p27+/+ or p27-/- MEF cells. Cell lysates were electrophoresed on SDS-PAGE gels and subjected to Western blotting with either total PR or phospho-Ser400 PR antibodies (P400). The PR phospho-Ser400 antibody recognized a non-specific protein (nsp) that migrated just under PR in MEF cells, that is not present in breast epithelial cells or HeLa cells.

Figure 8. PR Ser400 is required for ligand-independent PR transcriptional activity in p27-/- MEF cells. A. Increased PR transcriptional activity in p27-/- MEF cells. P27+/+ or p27-/- MEF cells were transiently transfected with PRE-luciferase and Renilla reporter plasmids and either wt or S400A PR-B (100ng) and 48 hrs after transfection, cell cultures were treated without or with R5020 for 18 hrs. PRE-luciferase activity in cell lysates was measured and normalized to Renilla controls. **B. PR dose-dependence of PR transcriptional activity in p27-/- MEF cells.** p27-/- cells were transiently transfected with increasing concentrations (10-250ng) of vectors expressing either wt or S400A PR-B, control empty vectors to normalize total cDNA concentrations, and a constant amount of PRE-luciferase reporter plasmid. PRE-luciferase activity in lysates from unstimulated cells was measured and is reported as relative luminometer units (RLUs). **C. Absence of ligand-independent PR transcriptional activity in p27+/+ cells.** P27+/+ MEF cells were transiently transfected with increasing concentrations of either wt or S400A PR-B (10-1000ng), control empty vector as appropriate, and a constant amount of PRE-luciferase reporter plasmid as in B and PRE-luciferase activity in lysates from unstimulated cells was measured. (Note difference in scales between Fig. 7B and C.) **D. RU486 blocks ligand-independent PR transcriptional activity in p27-/- cells.** p27-/- cells were transiently transfected with a PRE-luc reporter along with either 100 or 250 ng wt PR. 48 hrs following transfection, cultures were treated with 10^{-7} M RU486 or EtOH vehicle control and PRE-luciferase activity was measured and normalized to Renilla controls. The data are presented as means +/- standard deviations of

three replicates for each data point. Results are representative of 3-4 independent experiments.

Figure 9. Confocal microscopy showing the subcellular localization of wt and S400A PR. A. Delayed ligand-induced nuclear translocation of S400A PR. HeLa cells growing on cover slips in six-well dishes were transiently transfected with wt or S400A PR-B and treated with ETOH vehicle control or R5020 for either 1 or 3 hrs. The cells were fixed and subjected to immunohistochemistry with total PR monoclonal antibodies followed by FITC-conjugated secondary antibodies and PR stained cells were visualized by confocal microscopy. Controls for the primary and secondary antibodies demonstrated the specificity of PR staining (not shown). **B. Percent of transfected cells containing exclusively nuclear PR.** Transfected HeLa cells containing wt or S400A PR were prepared as in part A, counted (100 each), and the data was expressed graphically as the percent of transfected cells with PR exclusively in the nucleus relative to PR staining in both compartments. **C. Wild-type but not S400A PR nuclear association induced by activated CDK2.** HeLa cells growing on cover-slips in six-well dishes were transiently co-transfected with either wt or S400A PR-B along with mutant CDK2-TY or empty vector control. PR in transfected cells was immunostained as above with total PR monoclonal antibodies followed by FITC-conjugated secondary antibodies. PR transfected cells were visualized by confocal microscopy. **D. Percent of cells with exclusively nuclear PR.** HeLa cells transfected with either wt or S400A PR

were prepared as in part C and counted (100 each), and the data was expressed

graphically as the percent of cells with PR exclusively in the nucleus relative to

both cytoplasmic and nuclear compartments. **E. p27 and CDK2-dependent**

cytoplasmic retention of liganded PR. HeLa cells growing on cover-slips in

six-well dishes were transiently transfected with wt PR-B and either empty vector

control, or vectors encoding wt p27 or a p27^{ck-} mutant unable to bind CDK2, and

48 hrs later, transfected cells were treated with R5020 for 1 hour. Cells were

stained with PR-specific monoclonal antibodies as above and visualized by

confocal microscopy. These experiments were repeated 2 times in HeLa cells

and 1 time in MDA-MB-435 cells with similar results.

1. **Alkarain, A., R. Jordan, and J. Slingerland.** 2004. p27 Deregulation in Breast Cancer: Prognostic Significance and Implications for Therapy. J Mammary Gland Biol Neoplasia **9**:67-80.
2. **Ansieau, S., E. Kowenz-Leutz, R. Dechend, and A. Leutz.** 1997. B-Myb, a repressed trans-activating protein. J Mol Med **75**:815-9.
3. **Bain, D. L., M. A. Franden, J. L. McManaman, G. S. Takimoto, and K. B. Horwitz.** 2000. The N-terminal region of the human progesterone A-receptor. Structural analysis and the influence of the DNA binding domain. J Biol Chem **275**:7313-20.
4. **Bamberger, A. M., C. M. Bamberger, B. Gellersen, and H. M. Schulte.** 1996. Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci U S A **93**:6169-74.
5. **Bartkova, J., J. Lukas, H. Muller, D. Lutzhoft, M. Strauss, and J. Bartek.** 1994. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer **57**:353-61.
6. **Berthet, C., E. Aleem, V. Coppola, L. Tessarollo, and P. Kaldis.** 2003. Cdk2 knockout mice are viable. Curr Biol **13**:1775-85.
7. **Catzavelos, C., N. Bhattacharya, Y. C. Ung, J. A. Wilson, L. Roncari, C. Sandhu, P. Shaw, H. Yeger, I. Morava-Protzner, L. Kapusta, E. Franssen, K. I. Pritchard, and J. M. Slingerland.** 1997. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med **3**:227-30.

8. **Cesi, V., B. Tanno, R. Vitali, C. Mancini, M. L. Giuffrida, B. Calabretta, and G. Raschella.** 2002. Cyclin D1-dependent regulation of B-myb activity in early stages of neuroblastoma differentiation. Cell Death Differ **9**:1232-9.

9. **Chen, Z., V. B. Indjeian, M. McManus, L. Wang, and B. D. Dynlacht.** 2002. CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell **3**:339-50.

10. **Chlebowski, R. T., S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass, D. Lane, R. J. Rodabough, M. A. Gilligan, M. G. Cyr, C. A. Thomson, J. Khandekar, H. Petrovitch, and A. McTiernan.** 2003. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. Jama **289**:3243-53.

11. **Clarke, C. L., and R. L. Sutherland.** 1990. Progestin regulation of cellular proliferation. Endocr Rev **11**:266-301.

12. **Coats, S., P. Whyte, M. L. Fero, S. Lacy, G. Chung, E. Randel, E. Firpo, and J. M. Roberts.** 1999. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells. Curr Biol **9**:163-73.

13. **Davis, S. T., B. G. Benson, H. N. Bramson, D. E. Chapman, S. H. Dickerson, K. M. Dold, D. J. Eberwein, M. Edelstein, S. V. Frye, R. T. Gampe Jr, R. J. Griffin, P. A. Harris, A. M. Hassell, W. D. Holmes, R. N. Hunter, V. B. Knick, K. Lackey, B. Lovejoy, M. J. Luzzio, D. Murray, P. Parker, W. J. Rocque, L. Shewchuk, J. M. Veal, D. H. Walker, and L. F. Kuyper.** 2001. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science **291**:134-7.

14. **Davison, E. A., C. S. Lee, M. J. Naylor, S. R. Oakes, R. L. Sutherland, L. Hennighausen, C. J. Ormandy, and E. A. Musgrove.** 2003. The cyclin-dependent kinase inhibitor p27 (Kip1) regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy. Mol Endocrinol **17**:2436-47.

15. **Doisneau-Sixou, S. F., C. M. Sergio, J. S. Carroll, R. Hui, E. A. Musgrove, and R. L. Sutherland.** 2003. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer **10**:179-86.

16. **Fantl, V., G. Stamp, A. Andrews, I. Rosewell, and C. Dickson.** 1995. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev **9**:2364-2372.

17. **Felzien, L. K., S. Farrell, J. C. Betts, R. Mosavin, and G. J. Nabel.** 1999. Specificity of cyclin E-Cdk2, TFIIB, and E1A interactions with a common domain of the p300 coactivator. Mol Cell Biol **19**:4241-6.

18. **Fisk, H. A., and M. Winey.** 2001. The mouse Mps1p-like kinase regulates centrosome duplication. Cell **106**:95-104.

19. **Font de Mora, J., and M. Brown.** 2000. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol **20**:5041-7.

20. **Geng, Y., Q. Yu, E. Sicinska, M. Das, J. E. Schneider, S. Bhattacharya, W. M. Rideout, R. T. Bronson, H. Gardner, and P. Sicinski.** 2003. Cyclin E ablation in the mouse. Cell **114:**431-43.

21. **Gillett, C., V. Fantl, R. Smith, C. Fisher, J. Bartek, C. Dickson, D. Barnes, and G. Peters.** 1994. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res **54:**1812-7.

22. **Gray, S.** 2003. Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet **362:**1332; author reply 1332.

23. **Groshong, S. D., G. I. Owen, B. Grimison, I. E. Schauer, M. C. Todd, T. A. Langan, R. A. Sclafani, C. A. Lange, and K. B. Horwitz.** 1997. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol **11:**1593-1607.

24. **Guiochon-Mantel, A., P. Lescop, S. Christin-Maitre, H. Loosfelt, M. Perrot-Applanat, and E. Milgrom.** 1991. Nucleocytoplasmic shuttling of the progesterone receptor. Embo J **10:**3851-9.

25. **Hissom, J. R., and M. R. Moore.** 1987. Progestin effects on growth in the human breast cancer cell line T-47D--possible therapeutic implications. Biochemical and Biophysical Research Communications **145:**706-711.

26. **Horstmann, S., S. Ferrari, and K. H. Klempnauer.** 2000. Regulation of B-Myb activity by cyclin D1. Oncogene **19:**298-306.

27. **Horwitz, K. B., M. B. Mockus, and B. A. Lessey.** 1982. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell **28:**633-642.

28. **Hunter, T., and J. Pines.** 1994. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell **79:**573-82.

29. **Ismail, P. M., P. Amato, S. M. Soyal, F. J. DeMayo, O. M. Conneely, B. W. O'Malley, and J. P. Lydon.** 2003. Progesterone involvement in breast development and tumorigenesis--as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids **68:**779-87.

30. **Jackman, M., Y. Kubota, N. den Elzen, A. Hagting, and J. Pines.** 2002. Cyclin A- and cyclin E-Cdk complexes shuttle between the nucleus and the cytoplasm. Mol Biol Cell **13:**1030-45.

31. **Jans, D. A., and S. Hubner.** 1996. Regulation of protein transport to the nucleus: central role of phosphorylation. Physiol Rev **76:**651-85.

32. **Jiang, W., G. Jimenez, N. J. Wells, T. J. Hope, G. M. Wahl, T. Hunter, and R. Fukunaga.** 1998. PRC1: a human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol Cell **2:**877-85.

33. **Johnson, T. K., R. E. Schweppe, J. Septer, and R. E. Lewis.** 1999. Phosphorylation of B-Myb regulates its transactivation potential and DNA binding. J Biol Chem **274:**36741-9.

34. **Keyomarsi, K., N. O'Leary, G. Molnar, E. Lees, H. J. Fingert, and A. B. Pardee.** 1994. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res **54:**380-5.

35. **Kim, T. Y., and W. G. Kaelin, Jr.** 2001. Differential control of transcription by DNA-bound cyclins. Mol Biol Cell **12**:2207-17.

36. **Knotts, T. A., R. S. Orkiszewski, R. G. Cook, D. P. Edwards, and N. L. Weigel.** 2001. Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem **276**:8475-83.

37. **Krek, W., M. E. Ewen, S. Shirodkar, Z. Arany, W. G. Kaelin, Jr., and D. M. Livingston.** 1994. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell **78**:161-72.

38. **Krek, W., and E. A. Nigg.** 1991. Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. Embo J **10**:3331-41.

39. **Labriola, L., M. Salatino, C. J. Proietti, A. Pecci, O. A. Coso, A. R. Kornblihtt, E. H. Charreau, and P. V. Elizalde.** 2003. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol **23**:1095-111.

40. **Lane, S., P. Farlie, and R. Watson.** 1997. B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation. Oncogene **14**:2445-53.

41. **Lange, C. A.** 2004. Making Sense of Cross-Talk between Steroid Hormone Receptors and Intracellular Signaling Pathways: Who Will Have the Last Word? Mol Endocrinol **18**:269-78.

42. **Lange, C. A., J. K. Richer, T. Shen, and K. B. Horwitz.** 1998. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem **273**:31308-31316.

43. **Lange, C. A., T. Shen, and K. B. Horwitz.** 2000. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A **97**:1032-7.

44. **Ma, T., B. A. Van Tine, Y. Wei, M. D. Garrett, D. Nelson, P. D. Adams, J. Wang, J. Qin, L. T. Chow, and J. W. Harper.** 2000. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev **14**:2298-313.

45. **Moeller, S. J., E. D. Head, and R. J. Sheaff.** 2003. p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation. Mol Cell Biol **23**:3735-52.

46. **Moore, M. R.** 2004. A rationale for inhibiting progesterone-related pathways to combat breast cancer. Curr Cancer Drug Targets **4**:183-9.

47. **Moore, M. R., J. L. Conover, and K. M. Franks.** 2000. Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. Biochem Biophys Res Commun **277**:650-4.

48. **Muller-Tidow, C., W. Wang, G. E. Idos, S. Diederichs, R. Yang, C. Readhead, W. E. Berdel, H. Serve, M. Saville, R. Watson, and H. P.**

Koeffler. 2001. Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood **97**:2091-7.

49. **Muraoka, R. S., A. E. Lenferink, J. Simpson, D. M. Brantley, L. R. Roebuck, F. M. Yakes, and C. L. Arteaga.** 2001. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J Cell Biol **153**:917-32.

50. **Murphy, C. S., J. J. Pink, and V. C. Jordan.** 1990. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res **50**:7285-92.

51. **Murphy, L., T. Cherlet, A. Lewis, Y. Banu, and P. Watson.** 2003. New insights into estrogen receptor function in human breast cancer. Ann Med **35**:614-31.

52. **Musgrove, E. A., C. S. Lee, M. F. Buckley, R. L. Sutherland, T. C. Wang, R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt.** 1994. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A **91**:8022-8026.

53. **Musgrove, E. A., C. S. Lee, and R. L. Sutherland.** 1991. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol **11**:5032-5043.

54. **Nandi, S., R. C. Guzman, and J. Yang.** 1995. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A **92**:3650-7.

55. **Narayanan R, A. A., Edwards DP, Weigel NL.** 2003. Presented at the Program of the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA.

56. **Nardulli, A. M., and B. S. Katzenellenbogen.** 1988. Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology **122**:1532-1540.

57. **Norbury, C., M. MacFarlane, H. Fearnhead, and G. M. Cohen.** 1994. Cdc2 activation is not required for thymocyte apoptosis. Biochem Biophys Res Commun **202**:1400-6.

58. **Okuda, M., H. F. Horn, P. Tarapore, Y. Tokuyama, A. G. Smulian, P. K. Chan, E. S. Knudsen, I. A. Hofmann, J. D. Snyder, K. E. Bove, and K. Fukasawa.** 2000. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell **103**:127-40.

59. **Ortega, S., I. Prieto, J. Odajima, A. Martin, P. Dubus, R. Sotillo, J. L. Barbero, M. Malumbres, and M. Barbacid.** 2003. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet **35**:25-31.

60. **Parisi, T., A. R. Beck, N. Rougier, T. McNeil, L. Lucian, Z. Werb, and B. Amati.** 2003. Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. Embo J **22:**4794-803.

61. **Perkins, N. D., L. K. Felzien, J. C. Betts, K. Leung, D. H. Beach, and G. J. Nabel.** 1997. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science **275:**523-7.

62. **Petersen, B. O., J. Lukas, C. S. Sorensen, J. Bartek, and K. Helin.** 1999. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. Embo J **18:**396-410.

63. **Porter, P. L., K. E. Malone, P. J. Heagerty, G. M. Alexander, L. A. Gatti, E. J. Firpo, J. R. Daling, and J. M. Roberts.** 1997. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med **3:**222-5.

64. **Pratt, W. B., and D. O. Toft.** 2003. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) **228:**111-33.

65. **Qiu, M., and C. A. Lange.** 2003. MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol **85:**147-57.

66. **Qiu, M., A. Olsen, E. Faivre, K. B. Horwitz, and C. A. Lange.** 2003. Mitogen Activated Protein Kinase Regulates Nuclear Association of Human Progesterone Receptors. Molecular Endocrinology.

67. **Reid, G., M. R. Hubner, R. Metivier, H. Brand, S. Denger, D. Manu, J. Beaudouin, J. Ellenberg, and F. Gannon.** 2003. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell **11:**695-707.

68. **Robinson, C., Y. Light, R. Groves, D. Mann, R. Marias, and R. Watson.** 1996. Cell-cycle regulation of B-Myb protein expression: specific phosphorylation during the S phase of the cell cycle. Oncogene **12:**1855-64.

69. **Said, T. K., R. C. Moraes, U. Singh, F. S. Kittrell, and D. Medina.** 2001. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ **12:**285-95.

70. **Sala, A., M. Kundu, I. Casella, A. Engelhard, B. Calabretta, L. Grasso, M. G. Paggi, A. Giordano, R. J. Watson, K. Khalili, and C. Peschle.** 1997. Activation of human B-MYB by cyclins. Proc Natl Acad Sci U S A **94:**532-6.

71. **Salghetti, S. E., A. A. Caudy, J. G. Chenoweth, and W. P. Tansey.** 2001. Regulation of transcriptional activation domain function by ubiquitin. Science **293:**1651-3.

72. **Salghetti, S. E., S. Y. Kim, and W. P. Tansey.** 1999. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. Embo J **18:**717-26.

73. **Salghetti, S. E., M. Muratani, H. Wijnen, B. Futcher, and W. P. Tansey.** 2000. Functional overlap of sequences that activate transcription and

signal ubiquitin-mediated proteolysis. Proc Natl Acad Sci U S A **97**:3118-23.

74. **Santen, R. J., R. X. Song, R. McPherson, R. Kumar, L. Adam, M. H. Jeng, and W. Yue.** 2002. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol **80**:239-56.

75. **Santilli, G., M. N. Cervellera, T. K. Johnson, R. E. Lewis, S. Iacobelli, and A. Sala.** 2001. PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites. Oncogene **20**:8167-74.

76. **Sartorius, C. A., S. D. Groshong, L. A. Miller, R. L. Powell, L. Tung, G. S. Takimoto, and K. B. Horwitz.** 1994. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B- receptors are switched to transcriptional agonists by cAMP. Cancer Res **54**:3868-77.

77. **Scott, K. A., and R. A. Walker.** 1997. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J Cancer **76**:1288-92.

78. **Shen, T., K. B. Horwitz, and C. A. Lange.** 2001. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol **21**:6122-31.

79. **Sheridan, P. L., R. M. Evans, and K. B. Horwitz.** 1989. Phosphotryptic peptide analysis of human progesterone receptor. New phosphorylated sites formed in nuclei after hormone treatment. J Biol Chem **264**:6520-8.

80. **Sicinski, P., J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, S. Z. Haslam, R. T. Bronson, S. J. Elledge, and R. A. Weinberg.** 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell **82**:621-30.

81. **Sicinski, P., and R. A. Weinberg.** 1997. A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia **2**:335-42.

82. **Sutherland, R. L., and E. A. Musgrove.** 2002. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res **4**:14-7.

83. **Sutherland, R. L., O. W. J. Prall, C. K. W. Watts, and E. A. Musgrove.** 1998. Estrogen and Progestin Regulation of Cell Cycle Progression. Journal of Mammary Gland Biology and Neoplasia **3**:63-72.

84. **Sweeney, K. J., B. Sarcevic, R. L. Sutherland, and E. A. Musgrove.** 1997. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene **14**:1329-40.

85. **Takimoto, G. S., D. M. Tasset, A. C. Eppert, and K. B. Horwitz.** 1992. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: Analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc. Natl. Acad. Sci. USA **89**:3050-3054.

51

86. **Tan, M., J. Yao, and D. Yu.** 1997. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res **57**:1199-205.

87. **Tan, P., B. Cady, M. Wanner, P. Worland, B. Cukor, C. Magi-Galluzzi, P. Lavin, G. Draetta, M. Pagano, and M. Loda.** 1997. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res **57**:1259-63.

88. **Tokuyama, Y., H. F. Horn, K. Kawamura, P. Tarapore, and K. Fukasawa.** 2001. Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J Biol Chem **276**:21529-37.

89. **Topper, Y. J., and C. S. Freeman.** 1980. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev **60**:1049-106.

90. **Trowbridge, J. M., I. Rogatsky, and M. J. Garabedian.** 1997. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci U S A **94**:10132-7.

91. **Vlach, J., S. Hennecke, and B. Amati.** 1997. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. Embo J **16**:5334-44.

92. **Wang, Z., and M. J. Garabedian.** 2003. Modulation of glucocorticoid receptor transcriptional activation, phosphorylation, and growth inhibition by p27Kip1. J Biol Chem **278**:50897-901.

93. **Weigel, N. L.** 1996. Steroid hormone receptors and their regulation by phosphorylation. Biochem J **319**:657-667.

94. **Xu, M., K. A. Sheppard, C. Y. Peng, A. S. Yee, and H. Piwnica-Worms.** 1994. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol **14**:8420-31.

95. **Zhang, Y., C. A. Beck, A. Poletti, J. P. Clement, P. Prendergast, T. T. Yip, T. W. Hutchens, D. P. Edwards, and N. L. Weigel.** 1997. Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol **11**:823-832.

96. **Zhang, Y., C. A. Beck, A. Poletti, D. P. Edwards, and N. L. Weigel.** 1995. Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol **9**:1029-1040.

97. **Zhang, Y., C. A. Beck, A. Poletti, D. P. Edwards, and N. L. Weigel.** 1994. Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem **269**:31034-31040.

98. **Zhao, J., B. K. Kennedy, B. D. Lawrence, D. A. Barbie, A. G. Matera, J. A. Fletcher, and E. Harlow.** 2000. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev **14**:2283-97.

99. **Ziebold, U., O. Bartsch, R. Marais, S. Ferrari, and K. H. Klempnauer.** 1997. Phosphorylation and activation of B-Myb by cyclin A-Cdk2. Curr Biol **7**:253-60.

100. **Zwijsen, R. M., E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards, and R. J. Michalides.** 1997. CDK-independent activation of estrogen receptor by cyclin D1. Cell **88**:405-15.

Figure 1

Figure 2

A.

CDK2i − + − +
R5020 − − + +

P400

Total PR

B.

CDK2i − − + +
EGF − + − −

P400

Total PR

C.

Ad-E
Ad-control
IgG control
Active E/K2

HH1

D.

Ad-E   Ad-control

+ + − −
− + − + R5020

Total PR

P400

Cyclin E

Actin

E.

− + − + − + CDK2i

PR

Actin

Figure 3

Figure 4

A.

B.

Figure 5

A.

B.

MDA-MB-435

C.

MDA-MB-435

Figure 6

A.

B.

Figure 7

A.

HH1

B.

←P400
←nsp

Total PR

Figure 8

A.

B.

C.

D.

Figure 9

A.

WT PR | S400A PR

(-) R5020

(+) R5020
1 hr.

(+) R5020
3 hrs.

B.

% of cells with nuclear PR

100
80
60
40
20

◆ wt PR
▲ S400A PR

(-)   (+)   (+)   R5020
     1hr   3hr

C.

Wt PR | S400A PR

(-)
CDK2-TY

(+)
CDK2-TY

D.

% of cells with nuclear PR

100
80
60
40
20

□ (+) CDK2-TY
■ (-) CDK2-TY

wt PR   S400A PR

E.

wt PR

Vector control | p27 | p27 ck-

R5020
1hr.